BIOMAT Database Logo BIOMAT Database Logo

Antagonism of fludrocortisone by spironolactone and canrenone. 1976

G J Huston, and P Turner

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011245 Pregnadienes Pregnane derivatives containing two double bonds anywhere within the ring structures.
D002192 Canrenone A synthetic pregnadiene compound with anti-aldosterone activity. 11614 R.P.,Aldadiene,Phanurane,SC-9376,R.P., 11614,SC 9376,SC9376
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005438 Fludrocortisone A synthetic mineralocorticoid with anti-inflammatory activity. 9-Fluorocortisol,9 alpha Fludrohydrocortisone,9 alpha-Fluoro-17-Hydroxycorticosterone,9 alpha-Fluorohydrocortisone,9-Fluoro-17-Hydroxycortisone,9-Fluorohydrocortisone,Astonin,Astonin Merck,Astonin-H,FCOL,9 Fluoro 17 Hydroxycortisone,9 Fluorocortisol,9 Fluorohydrocortisone,9 alpha Fluoro 17 Hydroxycorticosterone,9 alpha Fluorohydrocortisone,Astonin H,Merck, Astonin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G J Huston, and P Turner
[Acetylation of spironolactone, canrenone and 2-methyl-canrenone].
February 1995, Archiv der Pharmazie,
G J Huston, and P Turner
Enhancement by food of canrenone bioavailability from spironolactone.
July 1977, Clinical pharmacology and therapeutics,
G J Huston, and P Turner
Canrenone--the principal active metabolite of spironolactone?
August 1976, British journal of clinical pharmacology,
G J Huston, and P Turner
Is canrenone the major metabolite of spironolactone?
January 1983, Clinical pharmacy,
G J Huston, and P Turner
[Aspects of the physiologic bioavailability of spironolactone and canrenone].
November 1976, Semaine des hopitaux. Therapeutique,
G J Huston, and P Turner
Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.
June 1973, The Journal of pharmacology and experimental therapeutics,
G J Huston, and P Turner
Suppression by the spironolactone metabolite canrenone of plasma testosterone in man.
January 1974, Naunyn-Schmiedeberg's archives of pharmacology,
G J Huston, and P Turner
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
May 2014, Expert opinion on pharmacotherapy,
G J Huston, and P Turner
Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats.
January 1974, Naunyn-Schmiedeberg's archives of pharmacology,
G J Huston, and P Turner
Spironolactone response related to plasma canrenone concentration [proceedings].
April 1979, British journal of clinical pharmacology,
Copied contents to your clipboard!